

## عنوان مقاله:

Molecular basis of ovarian cancer and targeted therapy

## محل انتشار:

سومین سمپوزیوم بین المللی سرطان نسترن (سال: 1396)

تعداد صفحات اصل مقاله: 1

## نویسندگان:

Vahideh Keyvani - *Department Of Genetics, Faculty Of Sciences, Shahid Chamran University, Ahvaz, Iran*

Seyed Reza Kazemi Nezhad - *Department Of Genetics, Faculty Of Science Shahid Chamran University, Ahvaz, Iran*

Mohammadreza Abaszadegan - *Division Of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University Of Medical Sciences, Mashhad, Iran*

## خلاصه مقاله:

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Ovarian cancer is a common reason of death. For example, in Iran, ovarian cancer is a common neoplasm, grade as the 8th most frequent for incidence. A five-year survival of ovarian cancer patients in Iran is estimated to be 61%. For this reason, the study of the molecular mechanisms and targeted therapy of ovarian cancer is very important. A number of molecules have been itemized to be elaborate in the tumorigenic progression of invasion, metastasis and resistance to treatment. Molecular studies in all types of ovarian cancer have shown the influence of certain genes that are altered, activated (oncogenes), or inactivated (onco-suppressor genes). These changes may occur at the establishment of the progress of neoplastic events, and detection of these alterations in certain genes may be of clinical importance for the early diagnosis and the valuation of the progress of malignancy and targeted therapy. Many targeted agents have been examined in the therapy of ovarian cancer in clinical trials. These targets include VEGFR- and EGFR-signaling cascades. Currently, antiangiogenic agents are moving from Phase II to III clinical trials in ovarian cancer. Several Phase II and III trials are currently evaluating PARP inhibitor in combination with chemotherapy. Also phase II trial of 837 patients with ovarian cancer treated with anti-HER2 monoclonal antibody, showed only 7.3% of the 41 ERBB2-positive patients responded to treatment. Hence, the drugs are known as targeted therapy assistance to stop cancer from developing and diffusion. The aim of the present review is to provide a report of the recent works concerning the molecular biology of ovarian cancer and new targeted therapy of this cancer.

## کلمات کلیدی:

Ovarian Cancer, Cell and Cancer, Cancer Stem Cells, Targeted Cancer Therapy, Chemotherapy

## لینک ثابت مقاله در پایگاه سیویلیکا:

<https://civilica.com/doc/701011>



